Introduction
The rotator cuff (RC) is a group of muscles and associated tendons that are essential for shoulder stability and motion. RC tears are an exceedingly common musculoskeletal condition, the prevalence of which is estimated to be up to 50% of the US population and higher in older individuals (1) . To date, RC injury research has largely focused on improving healing at the bone-tendon interface in an attempt to repair the native enthesis, while the treatment of muscle atrophy and fibro-adipogenic degeneration observed in the setting of large RC tears has been largely ignored. This is despite the fact that both atrophy and fibro-adipogenic degeneration of the muscle have been correlated with poor functional outcome and decreased strength following RC repair (2) and shown to be irreversible even in the setting of complete tendon-to-bone healing (3) . Muscle atrophy and fibro-adipogenic degeneration may impair tendon mechanics and diminish compliance of the myotendinous unit, which ultimately diminishes functionality of the repaired RC (4) (5) (6) . This characteristic fibro-adipogenic degeneration seen following massive RC tears is unique to RC muscle and not commonly observed in other skeletal muscles. Increased lipid deposition and fibrosis diminish tendon compliance, and these changes appear irreversible following repair (2) . Furthermore, atrophy of the RC musculature is associated with loss of strength and contractile amplitude, resulting in shoulder weakness and Massive tears of the rotator cuff (RC) are associated with chronic muscle degeneration due to fibrosis, fatty infiltration, and muscle atrophy. The microenvironment of diseased muscle often impairs efficient engraftment and regenerative activity of transplanted myogenic precursors. Accumulating myofibroblasts and fat cells disrupt the muscle stem cell niche and myogenic cell signaling and deposit excess disorganized connective tissue. Therefore, restoration of the damaged stromal niche with non-fibro-adipogenic cells is a prerequisite to successful repair of an injured RC. We generated from human embryonic stem cells (hES) a potentially novel subset of PDGFRβ + CD146 + CD34 -CD56pericytes that lack expression of the fibro-adipogenic cell marker PDGFR-α. Accordingly, the PDGFR-β + PDGFR-αphenotype typified non-fibro-adipogenic, non-myogenic, pericyte-like derivatives that maintained non-fibro-adipogenic properties when transplanted into chronically injured murine RCs. Although administered hES pericytes inhibited developing fibrosis at early and late stages of progressive muscle degeneration, transplanted PDGFR-β + PDGFR-α + human muscle-derived fibro-adipogenic progenitors contributed to adipogenesis and greater fibrosis. Additionally, transplanted hES pericytes substantially attenuated muscle atrophy at all tested injection time points after injury. Coinciding with this observation, conditioned medium from cultured hES pericytes rescued atrophic myotubes in vitro. These findings imply that non-fibroadipogenic hES pericytes recapitulate the myogenic stromal niche and may be used to improve cell-based treatments for chronic muscle disorders.
poor function (7) . Although surgical repair for small tears may yield acceptable clinical outcomes, repair of large tears is complicated by an unacceptably high re-tear rate. Myogenic cells have demonstrated promise in the regeneration of chronically injured RC (8) . However, fibrosis in diseased organs often disrupts efficient engraftment of functional progenitors because of a hostile microenvironment. For instance, the myogenicity of satellite cells may be compromised in the fibrotic muscle (9) . Therefore, treatments to reverse muscle fibro-adipogenesis seem to be a prerequisite for transplantation of myo-regenerative cells. Muscular fibroadipogenic degeneration originates in PDGFR-α + precursor cells present in the perivascular spaces of injured muscles (10) . PDGFR-β, which is expressed by pericytes, has also been identified on activated fibro-adipogenic precursors in the lung, kidney, and liver (11) . We have recently demonstrated that fibro-adipogenic precursors are typified by coexpression of PDGFR-β and PDGFR-α in cardiac and skeletal muscles (12, 13) . These results suggest a close developmental and anatomic relationship between native perivascular myo-regenerative cells and fibro-adipogenic progenitors. Consequently, transplantation of heterogenous mesodermal precursors, such as culture-expanded mesenchymal stem cells (14) , which are also of perivascular origin (15) , creates the risk of replenishing the degenerating muscle with PDGFR-α + fibro-adipogenic cells that may promote fibrotic and adipogenic tissue degeneration. Therefore, improved stem cell-based therapies, such as replenishment of the diseased stromal niche with regenerative cells to repair microenvironment damage, may facilitate engraftment of myogenic precursors and induce long-lasting myo-regeneration that is necessary for successful muscle healing. Furthermore, these transplanted cells should not contribute to fibro-adipogenesis that may impair myogenic regeneration.
Human pluripotent (embryonic or induced) stem cells (hPSCs) provide a plentiful source for generation of diverse cell types. Multiple protocols to differentiate hPSCs into mesenchymal stem-like cells (16) and perivascular cells (17) (18) (19) have been described. However, functional differentiation demonstrated that in most cases, hPSC mesodermal derivatives are heterogenous cell populations composed of a mixture of mesodermal progenitors that can be distinguished based on their differentiation potentials (e.g., osteo-/chondro-/ fibro-/adipogenic) and level of expression or lack of expression of characteristic sets of markers (20, 21) . Additionally, in vitro modifications evolve in long-term cultures, resulting in progressive cell maturation or acquirement of fibroblast-like characteristics (12) . Accordingly, we have developed a protocol for generation of PDGFR-β + PDGFR-αpericytes from human embryonic stem cells (hES), characterized their differentiation properties, and tested their therapeutic potential in the degenerated muscle using a clinically relevant mouse model of chronic RC tears (8, 13, 22) . We were able to generate large numbers of pericyte-like cells with a simple and reproducible protocol. A potentially novel marker combination, PDGFR-β + PDGFR-α -, defines non-fibro-adipogenic lineage-restricted pericytes (LR-PCs) that coexpress canonical pericyte markers. When transplanted into the chronically injured mouse RC, engrafted LR-PCs maintained their intrinsic non-fibro-adipogenic features in the degenerating environment and indirectly supported myo-regeneration. When administered at 2 and 6 weeks after injury, the time points that are correlated with development of fibrosis in injured RCs, LR-PCs effectively attenuated excess production of collagens. On the contrary, administered human muscle-derived fibro-adipogenic progenitors (FAPs) increased fibrosis in injured muscles regardless of the timing of injection. Additionally, myofiber atrophy, which is observed within a few days after injury and progresses for weeks, was markedly reduced at all tested time points of LR-PC administration, as compared with the lack of effect on muscle atrophy when FAPs were injected.
Results
Chronic injury of the murine RC muscle leads to fibro-adipogenic degeneration. Transection of the murine suprascapular nerve and supraspinatus tendons (TTDN) results in chronic injury of the RC that mirrors the clinical outcome in humans, characterized by progressive muscle atrophy and massive fibro-adipogenic degeneration. As we have previously demonstrated (8, 13) , examination of RC histological sections revealed stage-specific degenerative remodeling of the injured muscle in comparison with non-injured ( Figure 1A ) and sham-operated RC ( Figure 1B) at different time points after injury ( Figure 1 , A-F). Massive necrosis of myofibers and a rapid increase in muscle cellularity, indicative of acute inflammation and cell proliferation, was observed within 4 days after TTDN ( Figure 1C ). Transient muscle regeneration at 2 weeks after TTDN ( Figure 1D ) was accompanied by the development of fibro-adipocytic tissue (Figure 1 , D and J) and progressed to massive muscle degeneration due to replacement of atrophied muscle fibers by adipose tissue ( Figure 1E ) and development of collagen-producing fibrous scars (Figure 1 , G-K) within 6 weeks after TTDN. The severity of muscle deterioration further increased at 10 weeks after TTDN with larger adipocyte clusters ( Figure 1D ) and fibrotic areas ( Figure 1L ). Changes in muscle structure and myofiber regeneration were observed at the lateral side at 2 weeks after TTDN ( Figure 1 , M and N), and muscle damage increased and spread in a medial direction in the muscle belly over time ( Figure 1N ). Increasing fibro-adipogenic stimulus may alter the activity of transplanted therapeutic cells from regeneration to degeneration. In an attempt to overcome this problem, we aimed to generate stromal cell-like progenitors that are resistant to pro-fibro-adipogenic cues.
Derivation of non-fibro-adipogenic CD146 + PDGFR-αcells from hES. Progenitor cells were generated by prolonged induction of hES differentiation in endothelial growth medium. Flow cytometry analysis revealed robust generation of CD146 + CD45 -CD34cells with an efficiency of up to 90% cell differentiation within 14 days ( Figure 2A ). hES derivatives were then sorted by multicolor flow cytometry based on the expression of CD146 (perivascular, endothelial, and mesenchymal cell marker) and lack of expression of CD34 (hematopoietic, endothelial, and adventitial cell marker) and CD45 (hematopoietic cell marker) and were rapidly expanded in endothelial cell growth medium (EGM-2). Alternatively, expanded CD146 + CD45 -CD34cells dominated the culture at passage 2 without the need for cell sorting. Similar to pericytes (PCs) from spontaneously differentiating hPSCs (17) , and cultured FACS-sorted human native PCs (15) , hES derivatives stably expressed perivascular cell markers when expanded in culture (from passage 2 and up to passage 9), including CD146, PDGFR-β, and CD73, but did not express CD34 and CD45 (Figure 2A ). Regardless of cell passage, hES CD146 + CD34 -CD45 -PCs exhibited vasculogenic features when seeded in Matrigel, rearranging into tubular networks ( Figure 2B ). Mesenchymal stem cells have been the most commonly used therapeutic cells for immunomodulation and reconstitution of diseased tissues (23, 24) and were also tested for their ability to promote regeneration in chronically injured RC muscle (25) . However, the heterogeneity of conventional culture-derived mesenchymal stem cells increases the risk of replenishing the degenerating muscle with PDGFR-β + PDGFR-α + fibro-adipogenic mesodermal precursors (10, 12, 13) that will promote tissue degeneration. Flow cytometry analysis of coexpression of PDGFR-α with CD34, which defines pro-fibro-adipogenic precursors in muscle tissue (10, 12, 26) , revealed a lack of expression of both markers by hES PCs between passages 2 and 9 (Figure 2A ), implying that these cells are devoid of fibro-adipogenic features. In accordance, CD146 + PDGFR-β + PDGFR-α -hES PCs failed to differentiate into adipocytes in adipogenic culture ( Figure 2 , D and E) and similarly to non-induced PC ( Figure 2F ) did not take up the Oil Red O lipid dye ( Figure 2G ). Expanded hES PCs resisted TGF-β1-induced fibrosis even after 6 weeks of stimulation, as indicated by unaltered levels of collagen synthesis in fibrotic conditions and lack of expression of α-smooth muscle actin (α-SMA), a myofibroblast marker (Figure 2 , H-K). Additionally, expanded hES PCs did not express CD56 ( Figure 2C ), which demarcates human myogenic perivascular cells (14) , and in accordance rarely formed myotubes in myogenic culture conditions (data not shown). hES PCs were not osteogenic either, as assessed by absence of alizarin red staining in osteogenic Altogether, these findings suggest that prolonged exposure of hES PCs to growth factors and components that support endothelial cell proliferation preserve the non-fibro-adipogenic, non-osteogenic features of these cells. Characteristics of hES-derived LR-PCs were compared with those of counterpart cells derived from human skeletal muscles (deltoid and subscapularis). Flow cytometry analysis revealed that application of growth factor-enriched endothelial cell growth medium to muscle explant cultures resulted in the expansion of CD146 + cells composed of 2 subpopulations: CD146 + CD56 + cells and CD146 + CD56cells ( Figure 2N ). Only the PDGFR-β + CD146 + CD56cell subset, but not CD146 + CD56cells (data not shown), coexpressed PDGFR-α ( Figure 2N ). Coinciding with published data (12, 27, 28) , sorted and expanded PDGFR-α + CD56cells lacked myogenic potential ( Figure 2O ) in comparison with the myogenic PDGFR-α -CD56 + cell population that efficiently generated multinucleated myosin heavy chain-positive (MyHC + ) myotubes in identical culture conditions ( Figure 2P ). Additionally, expression of PDGFR-α was directly correlated with a high adipogenic potential of PDGFR-α + CD56cells ( Figure  2Q ), whereas only few adipocytes were detected in PDGFR-α -CD56 + adipogenic cultures ( Figure 2R ). As a confirmation of high fibrogenic potential, collagen production was rapidly and significantly upregulated within 4 days in cultures of PDGFR-α + CD56cells that were stimulated with the profibrogenic cytokine TGF-β1 ( Figure 2S ). These findings clearly demonstrate that application of endothelial factor-enriched medium does not change the intrinsic characteristics of skeletal muscle tissue-derived cell counterparts, either non-myogenic, fibro-adipogenic PDGFR-α + CD56cells (FAPs) or myogenic PDGFR-α -CD56 + cells, and supports the notion that this set of growth factors determine cell fate at early stages of progenitor specification from pluripotent stem cells.
Transplanted LR-PCs maintain non-fibro-adipogenic features. Lack of fibro-adipogenic differentiation properties implies that LR-PCs will be superior for the cell therapy of the chronically injured RC, regenerating muscle and not contributing to degenerative remodeling. To test this hypothesis, CM-DiI-labeled human LR-PCs were administered to chronically injured RC muscles of immunodeficient NOD/SCID mice. LR-PCs were injected at different time points corresponding with stage-specific remodeling of the RC after injury: (a) pro-fibro-adipogenesis stage at 5 days after TTDN, (b) intermediate stage of fibro-adipogenesis at 2 weeks after TTDN, and (c) end-stage fibro-adipogenesis at 6 weeks after TTDN ( Figure  3A) . Matched controls included cell injection into sham-operated RC and saline-and FAP-injected TTDN RC at 5 days, 2 weeks, and 6 weeks after surgery ( Figure 3A ). At 4 weeks after injection, CM-DiI + human cells were still detected in muscle interstitial spaces in proximity to myotubes of injured ( Figure 3 , B and D) or sham-operated RC (Figure 3 , C, F, and J). Furthermore, human cells were incorporated in the fibrotic scar in end-stage fibro-adipocytic muscles (at 6 and 10 weeks after TTDN) in all tested groups ( Figure  3 , G, H, I, K, and L). α-SMA is a marker of perivascular smooth muscle cells and myofibroblasts. Immunostaining of RC sections with cross-reactive anti-mouse and -human α-SMA antibodies demonstrated high α-SMA expression in blood vessel-residing cells (Figure 3 , C-L) but not in engrafted CM-DiI + cells in all sham and TTDN groups ( into myofibroblasts, either spontaneously or in response to fibrotic cues. We then evaluated whether the restricted adipogenic differentiation of cultured LR-PCs is stimulated when injected into sham-operated and injured RC, through quantification of CM-DiI + adipocyte progeny. Except for a few rare CM-DiI + adipocytes that were detected when LR-PCs were injected at the end stage of RC degeneration, at 6 weeks after TTDN, LR-PCs were devoid of adipogenic potential in vivo ( Figure 3G and Table 1 ), suggesting that engrafted cells were still unable to respond to prolonged environmental adipogenic cues. Finally, few CM-DiI + LR-PCs were detected fused to murine myofibers, independent of injection timing in all tested groups (Table 1) .
To evaluate the survival of implanted cells, CM-DiI + LR-PCs were stably transduced to express luciferase, and bioluminescence intensity was monitored at days 1, 7, 14, 21, and 28, using a luciferase-based live imaging system. The strong bioluminescence signal measured in all sham-operated and TTDN-injected groups at day 1 had significantly declined by day 7 and further diminished within 2 weeks ( Figure 4, A  and B ). It has been previously shown that with time, a sharp drop in bioluminescence can be followed by escalating measurements, indicative of selective cell proliferation or potential cell tumorigenesis (29) . The luciferase-LR-PC signal was not detected beyond 2 weeks after injection in all tested groups ( Figure 4B ). However, CM-DiI + LR-PCs were still detected in muscle interstitial spaces of sham-operated and TTDN RC at 4 weeks ( Figure 3A, groups B and C) and up to 6 weeks ( Figure 3A , group A) after surgery ( Figure 3C and Table 1 ), suggesting that signal loss can be partially attributed to cell migration away from the injection site. Quantification of CM-DiI + cell deposition within remodeling injured RCs revealed that recruitment of implanted cells into fibro-adipogenic scar tissue was significantly increased when cells were injected at 2 weeks after TTDN (P < 0.05) in comparison with cell injection at 4 days and 6 weeks after injury (Table 1) .
LR-PCs inhibit fibrosis but not adipogenesis in the injured RC. We next measured collagen accumulation, as a key mediator of muscle fibrosis, by picrosirius red staining and red pixel intensity quantification. As expected, a progressive increase in collagen production was observed up to 10 weeks after TTDN in all saline-, LR-PC-and human muscle FAP-injected groups A-C, regardless of the timing of injection ( Figure 5 , A-F). However, LR-PC injections tended to reduce collagen accumulation ( Figure 5G) , and a significant 2-fold reduction in fibrosis was measured when cells were injected at 2 weeks after TTDN, implying that LR-PCs exert the best prevention of fibrosis when administered at an earlier stage of muscle degeneration. In accordance, a significant increase in engraftment of LR-PCs within the developing fibro-adipogenic scar was only detected when cells were injected at 2 weeks after TTDN (Table 1) . Additionally, engrafted LR-PCs were entirely devoid of expression of the myofibroblast marker α-SMA, implying that LR-PCs did not contribute to the development of fibrosis when injected into sham-or TTDN-operated RC ( Figure 5 , H and I, and Table 1 ). Altogether, these findings strongly support the notion that LR-PCs maintain non-fibrotic differentiation potential in the healthy and fibrotic muscle. Human skeletal muscle-derived, PDGFR-α + CD56 -FAPs were used as compatible controls of transplantation experiments, and the effect of matched administered FAPs on the development of fibrosis was evaluated ( Figure 5 , F, G, and J). Significantly greater fibrosis was measured when FAPs were administered at early, (4 days), intermediate, (2 weeks) and late stages (6 weeks) of muscle degeneration ( Figure 5G ). Similar to LR-PCs, engrafted CM-DiI + FAPs could still be observed in sham and injured RC sections at 4 weeks after injection, but unlike LR-PCs, FAPs accumulated at the injection site and expressed α-SMA in injured muscle ( Figure 5J ). We next imaged areas of fatty infiltration in all tested groups (A-C) for quantification of adipocytes in RC sections stained with H&E ( Figure 6 , A-H). Administration of LR-PCs did not induce ( Figure 6I ) or directly contribute to muscle adipogenesis ( Figure 6 , J and K, and Table 1 ). Except for a trend toward reduction of adipocytes when injected 6 weeks after TTDN, LR-PCs did not inhibit adipogenesis at any other given time point of cell injection ( Figure 6I ). FAP administration ( Figure 6H ) did not affect the rate of fat accumulation in injured muscle. Overall, FAPs remained clustered at the injection site and were not recruited to regions of atrophied muscle, but CM-DiI + FAPs were still induced to differentiate into adipocytes at all time points of injection into injured fibro-adipogenic muscle ( Figure 6L) .
LR-PCs attenuate chronic muscle atrophy. Atrophy of the torn RC is concurrent with muscle degeneration and can be recognized on injured muscle sections by the reduction in the diameter of myofibers. The average myofiber cross section diameter in non-injured RC muscle was 80 ± 2.7 μm (n = 3 mice, at least 15 sections per mouse, total of 83 myofibers) and was set as the threshold diameter of non-atrophic myofibers. Although peripheral nuclei generally indicate healthy, mature myofibers, nuclei central to myofibers reflect regeneration, even though they are also encountered in centronuclear myopathies involving muscle denervation (29) (30) (31) . Accordingly, we classified and quantified the following distinct types of myofibers: (a) non-atrophic, with central nuclei; (b) non-atrophic, with peripheral nuclei; (c) atrophic, with central nuclei; and (d) atrophic, with peripheral nuclei. As expected, TTDN injury induced massive myofiber atrophy (70%-90%) in comparison with sham-operated controls within 6-10 weeks (Figure 7, A, B , D, and G). Of note, similar degrees of atrophy were apparent in both types of myofibers, peripheral (M) and centronuclear (CNM), indicative of accumulative muscle wasting and cycles of ineffective muscle regeneration ( Figure 7G ). The operation of LR-PC injection itself slightly damaged the muscle, inducing approximately 20%-30% of atrophy in both types of myofibers in all sham control groups, but this was nearly 4-fold less than TTDN-induced atrophy (Figure 7, A, B, and G) . LR-PCs did not differentiate into myotubes after injection (Table 1) This trend was observed in all treated groups (A-C), with significantly more atrophic CNMs in the proximity of implanted CD-DiI + LR-PCs in TTDN-injected RC than in matched CM-DiI + LR-PCinjected, sham-operated RC ( Figure 7H ). Conversely, injected FAPs were detected in interstitial spaces only in sham-operated RC ( Figure 7D ) and were clustered at the injection site in injured muscle (Figure 7E) . Additionally, FAPs were not recruited to regions of muscle atrophy regardless of time point of injection after TTDN ( Figure 7F ). Altogether, these findings demonstrate that non-fibro-adipogenic transplanted PCs are selectively recruited to sites of muscle damage where they attenuate chronic muscle atrophy. LR-PC culture-conditioned medium rescues atrophied myotubes. Absence of myogenic differentiation by engrafted LR-PCs suggests that these PCs prevent myofiber atrophy via secretion of factors. To test this hypothesis, we first induced atrophy of cultured murine C2C12 myotubes by starvation (myotube cultures that were not refed) or treatment with dexamethasone (32, 33) . LR-PCs were mitotically inactivated and maintained in growth factor-deprived DMEM supplemented with 10% FBS. Conditioned medium was collected after 24 and 48 hours and assessed for its ability to block dexamethasone-or starvation-induced atrophy of murine C2C12 myoblasts that were induced to fully fuse into myotubes for 3 days in culture ( Figure 8A ). Controls consisted of myotubes incubated with DMEM/10% FBS or matched conditioned medium for 24 hours. Myotube average width was not changed under these conditions, demonstrating that LR-PC-conditioned medium alone does not induce myotube atrophy or hypertrophy (Figure 8, B and C) . As was previously shown (32, 33) , addition of dexamethasone resulted in myotube atrophy with a significant dose-dependent decrease (P < 0.0005) in myotube average width (Figure 8, B and C) . Similarly, myotubes starved 4 days were substantially narrower (P < 0.0005) than control fed myotubes (Figure 8, B and D) . Conditioned medium from 24-hour LR-PC cultures effectively blocked dexamethasone-or starvation-induced atrophy within 24 hours. Conditioned medium collected after 48 hours was not more inhibitory of myofiber atrophy, implying that optimal concentration of active factors was reached within 24 hours (Figure 8 , C and D).
Discussion
Degenerative remodeling of injured muscle alters the cellular and extracellular composition of the supportive stroma and consequently leads to severe loss of functional myofibers. Additionally, robust development of adipose and fibrotic tissue, typically as a result of chronic muscle injury, often hinders successful engraftment of functional progenitors. We have recently demonstrated that fibro-adipogenic perivascular cells are typified by coexpression of PDGFR-β and PDGFR-α in mouse skeletal muscle (12, 13) . We decided to extend and validate these findings in human cells. With this aim, we generated a potentially novel line of lineage-restricted cells (LR-PCs) from hES, characterized as PDGFR-β + PDGFR-α -, which defines non-fibro-adipogenic pericyte-like cells, similar to their murine counterparts. Non-fibro-adipogenic characteristics of LR-PCs were preserved in long-term culture as well as the expression of other PC markers, such as CD146 and CD73. Not only did LR-PCs maintain non-fibro-adipogenic characteristics after transplantation into the highly fibro-adipogenic environment of the chronically injured muscle, but they also attenuated RC muscle atrophy and fibrosis through paracrine factors.
Myogenic cells may be therapeutic in the chronically injured RC. However, fibrosis in diseased organs often disrupts efficient engraftment of functional progenitors due to a hostile microenvironment. For instance, the myogenicity of satellite cells may be compromised in the fibrotic muscle (34) . Therefore, it is important for the development of improved stem cell-based therapies to distinguish FAPs from regenerative stromal cells for successful reconstruction of the deteriorating stromal niche. PDGFR-α-expressing, muscle-resident perivascular and interstitial stromal cells have been identified as FAPs, the presence of which is correlated with the development of fibrosis and fat accumulation in mouse muscle after acute (10, 12) or chronic (13) injury, as well as the severity of fibrosis in patients with Duchenne muscular dystrophy (27) . Besides being a useful fibro-adipogenic cell marker, the signaling receptor PDGFR-α functionally regulates fibrogenic responses associated with multiple cardiac, renal, and muscle pathologies. PDGFR-α is activated predominantly in FAP cells in regenerating muscle, mediating ERK1/2 and AKT downstream signaling (35) . Additionally, elevated PDGFR-α signaling in embryos leads to accelerated fibrosis and disruption of connective tissue development (36) . We demonstrate here that hES PCs uniformly express PDGFR-β, which has been implicated as a marker of fibro-adipogenesis as well. Conversely, PDGFR-β typifies mouse and human mesodermal perivascular precursors that exhibit long-term multilineage differentiation capability, including in the myogenic cell lineage (9, 15, 37) , indicating functional heterogeneity of PDGFR-β + cells and strongly suggesting that coexpression of PDGFR-α by PDGFR-β cells is a key determinant for identification of PDGFR-β + FAP cells. Supporting this definition, severe cardiac fibrosis was detected in PDGF-α-but not PDGF-β-overexpressing transgenic mice (38) , and we have recently demonstrated in PDGFR-β reporter mice that GFP + PDGFR-β + cells that coexpress PDGFR-α directly contribute to fibrotic degeneration in acutely (12) and chronically (13) injured skeletal muscle. In accordance, we demonstrate here that classification of mouse FAPs based on coexpression of PDGFR-β and PDGFR-α is also applicable for human cells, in the context of skeletal muscle wasting. PDGFR-β/PDG-FR-α-based identification and classification should be further validated by additional analysis of PDGFR-β/ PDGFR-α expression on human cells from multiple organs with functional differentiation assays.
Stemming of fibrosis and fat accumulation at any tested time point of LR-PC transplantation after muscle injury is extremely promising because a potential complication with usual regenerative cell injections is that these may follow a profibrotic pathway when no longer exposed to culture conditions that inhibit their differentiation potential or may secrete factors that increase the risk of adverse outcomes (39, 40) . Coinciding with these results, we have previously used the same model of chronically injured muscle to test the therapeutic effect of long-term expanded perivascular cells from human adipose tissue and demonstrated that these cells do not worsen muscle degeneration and indirectly diminish muscle atrophy (8) . Differing from human muscle-derived PCs that can adopt myogenic features immediately after purification (15) as well as after long-term culture (9) , LR-PCs rarely formed myotubes and only at very early passages (data not shown), indicating a lack of myogenic potential of LR-PCs, which persisted when cells were injected into regenerating muscles at 4 days and 2 weeks after injury. Overall, development of fibrosis involves activation of signaling cascades that induce migration of myofibroblasts to sites of injury. The fibrogenic response is initiated in chronically injured RC at 2 weeks after operation (13) , and in accordance we observed a marked increase in the recruitment of transplanted LR-PCs to regions of damaged muscle at 2 weeks after injury, implying stage-specific upregulation of factors that mediate stromal cell migration, such as TGF-β, PDGF-α/β, and Ang I (37, 38, 41) . Given that exposure of atrophied myotubes to LR-PC-conditioned medium was sufficient to significantly reduce atrophy in culture, further experiments will be carried out to identify and characterize the released therapeutic factors (free secreted growth factors and/or exosomes). Paracrine factors secreted by stromal cells may mediate tissue healing through inhibition of apoptosis, stimulation of cell proliferation, differentiation, modulation of immune-inflammatory reactions, and induction of neovascularization. A pivotal role of endothelial hepatocyte growth factor in the inhibition of lung fibrosis was attributed to suppression of the profibrotic expression of NOX4 in lung and liver perivascular cell-derived fibroblasts (42) . PC-derived insulin-like growth factor 1 (IGF-1) was identified as a secreted effector regulating myofiber growth in postnatal mice (43) , and injection of IGF-1 into mouse muscle with denervation-induced atrophy mediated a decrease in the expression of the atrophy-related genes MAFbx and MurF1 and rescued muscle mass (32) . Human skeletal muscle PCs express the promyogenic microRNA mir-206 (44) , which was shown to regulate skeletal muscle fiber hypertrophy and collagen deposition (45) . The results obtained from the in vitro atrophy experiments suggest that muscle atrophy is reduced regardless of anti-fibrotic effects that can be possibly linked to or independent of activation of anti-atrophic responses. Because LR-PC supernatant did not make normal myotubes hypertrophic, a compensatory hypertrophy targeted specifically to atrophied myotubes cannot be excluded.
Multiple protocols to differentiate hPSCs into mesodermal precursors and mesenchymal stem-like cells exist. However, functional differentiation testing demonstrates that in most cases, hPSC mesodermal derivatives are heterogenous cell populations composed of a mixture of mesodermal progenitors with distinct differentiation potentials (e.g., osteo-/chondro-/fibro-/adipogenic) and marker expressions (14) . Additionally, modifications take place in long-term cultures, resulting in progressive cell maturation or acquirement of fibroblast-like characteristics. Derivation of non-fibro-adipogenic cells from hPSCs provides a tool for unraveling the molecular mechanisms that determine cell differentiation fate and understanding mechanisms underlying gene expression and identifying novel precursors and sets of markers. Methods such as gene expression profiling of pluripotent stem cells at various stages of induced differentiation (46) , RNA-sequencing of murine muscle-derived FAPs at a single-cell level (47) , and comparison of human tissue microarray to human pericyte transcriptome (48) were used for comprehensive identification of progenitor subtypes and relevant markers. Similar studies will allow us to characterize a hierarchy of LR-PC precursors and involved molecular control of a non-fibro-adipogenic phenotype. Of note, when endothelial cell growth factor-enriched medium was used to establish cultures of stromal cells from human muscle explants, muscle-derived expanded cells maintained their intrinsic features in short-term and differentiation cultures. As was previously shown (9, 27) , although not tested at the conditions reported herein, human CD56 + cells do not express the fibro-adipogenic marker PDGFR-α and in accordance exhibited high myogenic features but no fibro-adipogenic potential, whereas CD56cells that express PDGFR-α displayed high fibro-adipogenic potential and no myogenic differentiation capability. These features were maintained following transplantation of PDGFR-α + FAPs into chronically injured muscles regardless of time point of injection. Our in vitro and in vivo findings clearly demonstrate that application of endothelial factor-enriched medium does not change the intrinsic characteristics of skeletal muscle tissue-derived cell counterparts, supporting the notion that this set of growth factors determine cell fate at early stages of progenitor specification from pluripotent stem cells.
The use of a novel, simple, and reproducible protocol for generation of non-fibro-adipogenic stromal cells that participate indirectly in the repair of chronically injured RC muscle and do not contribute to degenerative fibro-adipogenic remodeling may have valuable potential in the treatment of multiple muscle disorders. Furthermore, the strategies used in this research may be applicable not only to muscle regeneration but also to microenvironment reconstruction and potential repair in other tissues affected by fibrosis, such as lung, kidney, liver, and heart. Human pluripotent cell-based therapy has already reached the clinical trial stage (49) . We envision that this work will result in an autologous therapy that may be used perioperatively to decrease the morbidity of massive RC tears, as well as the failure rate of surgical repairs and resulting disability in millions of people.
Methods
Mice. NOD/SCID mice (females, 8-10 weeks old) purchased from The Jackson Laboratory (JAX 001303) were used for all experiments.
Cell cultures. hES (H9 cell line) were grown and maintained on hES-qualified Matrigel-coated plates in mTESR medium (Stem Cell Technologies) containing 0.4% penicillin/streptomycin (Hyclone), as previously described (46, 50) . All cell lines were tested for mycoplasma and were negative for mycoplasma contamination. Cell line identity was confirmed by karyotype analysis routinely using Cell Line Genetics. Differentiation was initiated when hES reached about 50% confluence, and hES medium was substituted with EGM-2 medium (Lonza) for 10-14 days. Differentiated adherent cell derivatives were then removed from the culture dish by 0.25% Trypsin-EDTA (Corning) for multisorting of CD146 + CD34 -CD45derivatives. Alternatively, CD146 + CD34 -CD45cells dominated the culture within 2 passages when expanded in EGM-2 without the need for cell sorting. Human deltoid and subscapularis were obtained with informed consent (n = 3), and muscle stromal cells were expanded in explant cultures supplemented with EGM-2. Confluent adherent cells were then removed (Trypsin-EDTA 0.25%) for multisorting of CD146 + CD56 + and CD146 + CD56cells. Sorted subsets were further expanded in EGM-2 for an additional 1-2 passages.
Flow cytometry and cell sorting. Differentiated and expanded hES PCs (passages 2-9) and human muscle cells from primary cultures were washed in PBS, centrifuged, and labeled according to the manufacturer's instructions with the following antibodies: PE-conjugated mouse anti-human PDGFR-β/CD140b (catalog 323605), PE-conjugated mouse anti-human PDGFR-α/CD140a (catalog 3235050), APC-conjugated mouse anti-human CD34 (catalog 343509), FITC-conjugated mouse anti-human CD45 (catalog 368508), APC-conjugated mouse anti-human CD56 (catalog 318310), and FITC-conjugated mouse anti-human CD73 (catalog 344015) from BioLegend and PE-conjugated mouse anti-human CD146 from BD Biosciences (catalog 550315). Cell sorting was performed using Aria II Flow Cytometer (BD Biosciences). Debris and dead cells were excluded according to forward and side scatter, and analyses were carried out using LSR II flow cytometer and BD FACSDiva (BD Biosciences).
In vitro differentiation assays. For adipogenic differentiation, cells were cultured in DMEM/10% FBS supplemented with 1 μM dexamethasone, 1 μM insulin, 0.5 mM IBMX (all from MilliporeSigma), and 1% pen/strep for 5 days. Adipogenic differentiation was assessed with Oil Red O staining (ScienCell Research Laboratories) for the presence of lipids according to manufacturer instructions. For osteogenic differentiation, cells were cultured in 10 mM β-glycerophosphate (Cayman Chemical) and 0.1 μM dexamethasone (MilliporeSigma) in Glasgow MEM BHK-21 medium (Gibco, Thermo Fisher Scientific) containing 10% FBS for up to 4 weeks. Cell cultures were assayed for calcium content by alizarin red staining. For myogenic differentiation cells were seeded on a Matrigel-coated dish at a concentration of 10 5 cells/cm 2 and cultured in DMEM supplemented with 2% horse serum. For myotube quantification cultures were fixed with 4% PFA for 10 minutes at room temperature, washed in PBS, and labeled with nuclear DAPI and rabbit anti-human striated MyHC. A MyHC + cell that contained more than 3 nuclei with typical morphology was considered a myotube. For induction of fibrosis, LR-PCs (passages 6-7) and CD146 + CD56 + and CD146 + CD56cells (passages 1-2) were seeded at a concentration of 3 × 10 5 cells/cm 2 and cultured in DMEM/10% FBS in the presence or absence of 5 ng/mL human TGF-β1 (R&D Systems). Triplicates were fixed and stained for collagen production using picrosirius red (Abcam) at 4 days, 2 weeks, and 6 weeks after induction. Extraction of picrosirius red was performed by using 0.1 M NaOH and collagen quantified using color spectrophotometry (λ = 540 mm).
RC injury model. Massive RC tear surgery was performed as previously described (13) . Briefly, the mice (8-10 weeks old) were anesthetized with 2% isoflurane and oxygen and administered buprenorphine for analgesia, and their right shoulders were sterilely prepared and draped. A 1-cm skin incision was made
